Seno Medical Instruments

Focus: Seno Medical Instruments is a diagnostic imaging specialist focused on breast cancer detection using optoacoustic ultrasound technology (Imagio platform). The company operates as a focused oncology diagnostics player in San Antonio, TX.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Seno Medical Instruments

AI assessmentNot Hiring

No open roles listed right now. Follow Seno Medical Instruments to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

Imagio OA/US

Breast Cancer / Breast Abnormality Diagnosis

Growth

Lead optoacoustic ultrasound platform with multiple indication and generation variants in active development.

Imagio IUS

Breast Cancer

Help build intelligence for Seno Medical Instruments

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Deep expertise in a high-unmet-need oncology segment (breast cancer diagnostics) with multiple Imagio platform iterations in development
Opportunity to shape emerging optoacoustic imaging technology before market consolidation or exit
Clinical operations role indicates active trial portfolio (9 active studies) with potential near-term regulatory milestones

Watch Out For

Only 1 active job opening signals minimal hiring velocity and limited upward mobility relative to larger competitors
Lack of published financials, funding data, and employee count suggests private status with opaque growth trajectory and sustainability risk

Generated by Claude from Seno Medical Instruments's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Next-generation iteration of core Imagio platform targeting breast cancer indication.